Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) shares are trading higher Monday after the company announced the exclusive license of potential therapeutic or preventative humanized anti-SARS-CoV-2 monoclonal antibodies from Curia Global.
What Happened: Tonix obtained an exclusive license from Curia Global for the development of three humanized murine monoclonal antibodies for the treatment or prophylaxis of SARS-CoV-2 infection, which causes COVID-19.
“The Company believes that murine monoclonal antibodies have the potential for neutralizing a broader spectrum of SARS-CoV-2 variants and may be harder for SARS-CoV-2 to evade as we face a ‘variant soup’ from both convergent and divergent evolution,” said Seth Lederman, CEO of Tonix.
The murine monoclonal antibodies and their humanized counterparts build on a base of knowledge from the company’s fully human monoclonal antibody platform, TNX-3600.
Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics to treat and prevent human disease and alleviate suffering.
See Also: Alibaba, Nio Stocks Drop: Hang Seng Opens Weaker As US Inflation Data, Fed Meet Eyed
TNXP Price Action: Tonix has a 52-week high of $14.08 and a 52-week low of 35 cents per share.
The stock was up 82.7% at 67 cents at time of publication, according to Benzinga Pro.
Photo: Masum Ali from Pixabay.
